Dr Reddy’s Laboratories announced the launch of Penicillamine Capsules USP, 250 mg, a therapeutic equivalent generic version of Cuprimine (penicillamine) capsules, 250 mg, approved by the US Food and Drug Administration (USFDA).
Penicillamine USP is a chelating agent used in the treatment of Wilson’s disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy.
The Cuprimine brand and generic market had US sales of approximately $80 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health.
Dr Reddy’s Penicillamine Capsules, USP is available as 250 mg capsules in a bottle count sizes of 100.